回盛生物
(300871)
| 流通市值：22.35亿 | | | 总市值：22.36亿 |
| 流通股本：1.66亿 | | | 总股本：1.66亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 200,426,131.74 | 362,695,913.25 | 395,545,161.51 | 424,044,443.62 |
| 应收票据及应收账款 | 329,466,758.23 | 310,941,773.42 | 335,416,681.47 | 347,953,545.43 |
| 其中：应收票据 | 11,415,209 | 7,422,459.5 | 8,445,120.44 | 9,964,296.14 |
| 应收账款 | 318,051,549.23 | 303,519,313.92 | 326,971,561.03 | 337,989,249.29 |
| 应收款项融资 | 19,349,743.5 | 9,279,211.32 | 1,449,453.26 | 6,457,806.79 |
| 预付款项 | 9,357,294.43 | 9,032,410.25 | 17,863,016.87 | 8,545,690.7 |
| 其他应收款合计 | 2,186,607.72 | 1,994,304.05 | 2,087,028.45 | 1,697,890.95 |
| 存货 | 237,613,539.52 | 249,542,510.38 | 217,506,790.94 | 199,006,300.16 |
| 其他流动资产 | 3,046,372.12 | 2,170,277.65 | 5,337,264.91 | 2,092,250.19 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,207,394,074.06 | 1,326,192,724.79 | 1,368,615,054.54 | 1,351,475,288.9 |
| 非流动资产: | | | | |
| 投资性房地产 | 11,338,850.93 | 11,513,255.35 | 11,687,659.77 | 11,862,064.19 |
| 固定资产 | 1,536,495,007.83 | 1,205,550,762.97 | 1,160,945,014.58 | 1,165,570,619.64 |
| 在建工程 | 26,219,471.97 | 305,579,287.02 | 356,062,252.37 | 332,508,298.19 |
| 无形资产 | 104,835,883.78 | 105,504,404.41 | 106,180,961.63 | 106,873,591.88 |
| 长期待摊费用 | 3,029,273.58 | 289,085.51 | 330,383.45 | 371,681.39 |
| 递延所得税资产 | 15,095,757.71 | 13,281,168.2 | 13,947,447.05 | 12,909,858.79 |
| 其他非流动资产 | 6,738,146.73 | 7,657,672.54 | 6,676,345.06 | 7,542,900.27 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,703,752,392.53 | 1,649,375,636 | 1,655,830,063.91 | 1,637,639,014.35 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,911,146,466.59 | 2,975,568,360.79 | 3,024,445,118.45 | 2,989,114,303.25 |
| 流动负债: | | | | |
| 短期借款 | 241,013,008.9 | 305,227,062.36 | 257,017,934.21 | 220,084,829.04 |
| 应付票据及应付账款 | 405,987,335.56 | 428,500,007.58 | 477,164,030.5 | 489,703,494.71 |
| 其中：应付票据 | 130,472,159.13 | 173,721,476.37 | 214,870,673.95 | 179,400,944.47 |
| 应付账款 | 275,515,176.43 | 254,778,531.21 | 262,293,356.55 | 310,302,550.24 |
| 合同负债 | 17,318,492.93 | 14,244,328.62 | 16,050,663.05 | 15,616,412.67 |
| 应付职工薪酬 | 18,873,757.83 | 15,207,834.51 | 13,808,784.13 | 27,165,986.34 |
| 应交税费 | 5,404,350.97 | 3,915,148.55 | 10,038,369.05 | 12,922,173.09 |
| 其他应付款合计 | 26,105,106.44 | 25,708,440.93 | 27,485,094.18 | 29,512,111.59 |
| 其他流动负债 | 7,455,808.5 | 8,524,417.32 | 9,889,219.96 | 9,920,289.25 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 722,157,861.13 | 801,327,239.87 | 811,454,095.08 | 804,925,296.69 |
| 非流动负债: | | | | |
| 应付债券 | 596,914,070.2 | 587,827,204.91 | 579,014,243.01 | 570,360,233.88 |
| 递延收益 | 63,082,283.63 | 55,602,636.5 | 54,706,989.44 | 48,888,649.2 |
| 递延所得税负债 | 19,987,284.44 | 20,785,793.37 | 21,291,046.53 | 21,817,902.59 |
| 其他非流动负债 | 1,690,000 | 1,690,000 | 1,690,000 | 1,690,000 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 681,673,638.27 | 665,905,634.78 | 656,702,278.98 | 642,756,785.67 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,403,831,499.4 | 1,467,232,874.65 | 1,468,156,374.06 | 1,447,682,082.36 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 165,887,158 | 165,887,155 | 166,054,574 | 166,054,539 |
| 其他权益工具 | 126,903,801.03 | 126,903,819.16 | 126,915,803.09 | 126,915,984.39 |
| 资本公积 | 874,006,689.38 | 874,006,607.45 | 877,083,187.43 | 877,082,235.63 |
| 减:库存股 | 52,421,063.28 | 52,421,063.28 | 55,730,993.28 | 55,730,993.28 |
| 盈余公积 | 50,889,318.96 | 50,889,318.96 | 50,889,318.96 | 50,889,318.96 |
| 未分配利润 | 342,049,063.1 | 343,069,648.85 | 391,076,854.19 | 376,221,136.19 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,507,314,967.19 | 1,508,335,486.14 | 1,556,288,744.39 | 1,541,432,220.89 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,507,314,967.19 | 1,508,335,486.14 | 1,556,288,744.39 | 1,541,432,220.89 |
| 负债和股东权益合计 | 2,911,146,466.59 | 2,975,568,360.79 | 3,024,445,118.45 | 2,989,114,303.25 |
| 公告日期 | 2023-10-30 | 2023-08-29 | 2023-04-27 | 2023-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |